2dOpinion
The therapy for the future
Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...
Leading RNA drug developer Suzhou Ribo Life Science Co. Ltd. passed its hearing for a listing on the Hong Kong Stock Exchange, marking the official launch of its IPO, according to its post-hearing ...
3d
Waliigaltee Ameerikaan Itoophiyaa dabalatee kaan waliin mallatteessisaa jirtu maaliif falmii kaase?
Ministeerri Fayyaa Itoophiyaa damee fayyaa biyyattii jabeessuuf mootummaa Ameerika waliin waliigaltee deeggarsaa doolaara ...
VESALIUS-CV was big in 2025, but studies looking at triglycerides, CRISPR, and oral GLP-1s also made the highlight reel.
TipRanks on MSN
CF PharmTech’s inhalable nucleic acid drug project selected for Jiangsu major science and technology program
An announcement from CF PharmTech. Inc. Class H ( ($HK:2652) ) is now available. CF PharmTech announced that its company-led project to develop ...
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...
6d
Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762
Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, ...
TheFly reported on December 16 that Oppenheimer raised its price target on WVE to $32 from $24 while maintaining an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback